Zacks Small-Cap Research

August 24, 2015
Tonya Wang, MBA
Grant Zeng, CFA
312-265-9466
gzeng@zacks.com

scr.zacks.com
10 S. Riverside Plaza, Chicago, IL 60606

CASI Pharma (CASI-NASDAQ)

CASI: Zevalin launched in Hong Kong, to initiate Phase II of ENMD-2076 for FLC in 3Q15 --Buy

Current Recommendation	**Buy**
Prior Recommendation	N/A
Date of Last Change	02/11/2015
Current Price (08/21/15)	$1.42
Twelve-Month Target Price	**$4.50**

OUTLOOK

CASI is a **commercial stage** biopharmaceutical company with a therapeutic focus on cancer and autoimmune diseases. Its lead oncology drug candidate ENMD-2076 is in multiple Phase II clinical trials in both North America and China. CASI is on track to initiate the import drug registration process for Zevalin™ and Marqibo™ in China and officially launched Zevalin in Hong Kong. CASI is also developing 2ME2 for autoimmune disorders.

CASI's unique dual development approach leverages its expertise and resources in both North America and greater China, which differentiates itself from local competitors in each of the territory.

We are optimistic about CASI's prospect and rating its shares Buy.

SUMMARY DATA

52-Week High	**$1.92**
52-Week Low	**$1.16**
One-Year Return (%)	**-19.09**
Beta	**1.43**
Average Daily Volume (sh)	**10,027**
Shares Outstanding (mil)	**32**
Market Capitalization ($mil)	**$46**
Short Interest Ratio (days)	**2.01**
Institutional Ownership (%)	**N/A**
Insider Ownership (%)	**N/A**
Annual Cash Dividend	**$0.00**
Dividend Yield (%)	**0.00**
5-Yr. Historical Growth Rates	
Sales (%)	**N/A**
Earnings Per Share (%)	**N/A**
Dividend (%)	**N/A**
P/E using TTM EPS	**N/A**
P/E using 2015 Estimate	**N/A**
P/E using 2016 Estimate	**N/A**
Zacks Rank	**N/A**

Risk Level	**High,**
Type of Stock	**Small-Growth**
Industry	**Med-Drugs**
Zacks Rank in Industry	**N/A**

ZACKS ESTIMATES

Revenue
(in millions of $)

	Q1 (Mar)	Q2 (Jun)	Q3 (Sep)	Q4 (Dec)	Year (Dec)
2014	0.00 A	0.00 A	0.00 A	0.00 A	0.00 A
2015	0.02 A	0.02 A	0.10 E	0.20 E	0.35 E
2016					0.50 E
2017					1.00 E

Earnings per Share
(EPS is operating earnings before non recurring items)

	Q1 (Mar)	Q2 (Jun)	Q3 (Sep)	Q4 (Dec)	Year (Dec)
2014	-$0.05 A	-$0.06 A	-$0.07 A	-$0.05 A	-$0.23 A
2015	-$0.06 A	-$0.06 A	-$0.06 E	-$0.06 E	-$0.24 E
2016					-$0.23 E
2017					-$0.23 E

Zacks Projected EPS Growth Rate - Next 5 Years % **N/A**

© Copyright 2015, Zacks Investment Research. All Rights Reserved.

WHAT'S NEW

Update on Second Quarter Financials

On August 14, CASI reported financial results for the fiscal second quarter ended June 30, 2015.

There was no meaningful revenue for the second quarter of 2015, as compared to no revenue for the second quarter of 2014.

R&D expenses for second quarter of 2015 were $1.2 million, as compared to 0.7 million for the second quarter of 2014. The increase in R&D expenses in 2Q15 was primarily due to higher clinical trial costs associated with the company's food effect study of ENMD-2076 in healthy human subjects, an increase in patient enrollment on other clinical trials, as well as increased costs associated with research and development operations in China during 2015.

G&A expenses for second quarter of 2015 were $0.86 million, compared to $0.89 million for the second quarter of 2014. This decrease in G&A expenses in 2Q15 reflected lower non-cash stock-based compensation expense, partially offset by an increase in foreign patent related costs.

Net loss for the second quarter of 2015 was $2.1 million ($0.06 per share), compared to a net loss of $1.6 million ($0.06 per share) for the same period last year.

As of June 30, 2015, CASI had cash and cash equivalents of approximately $8.0 million. The current cash balance should be able to fund the company's operations into 3Q2016 according to our financial model.

Also CASI received investments from IDG ACCEL and Kleiner Perkins Caufield & Byers China, two major venture capital firms in China. These firms tend to have long-term investment strategies, have representatives on the company's Board of Directors and are in line with the company's mission.

The financial results for second quarter of 2015 were in line with our expectations. We see the financial report as a non-event for CASI. Investors should be focused on CASI's clinical development as well as the company's import drug business. In this regard, we think CASI has made great progress in the second quarter of 2015.

Update on ENMD-2076 in FLC

In early June 2015, CASI filed an application with China's Food and Drug Administration (CFDA) to conduct a **Phase II** clinical trial in fibrolamellar carcinoma **(FLC)** patients in China for its lead proprietary drug candidate, ENMD-2076.

This is CASI's fourth application to conduct a new drug clinical trial in China for ENMD-2076. The company has received approval of ENMD-2076 for three other applications to conduct trials in ovarian clear cell carcinoma, soft tissue sarcoma, and triple negative breast cancer (TNBC), the latter of which was initiated recently and is currently enrolling patients.

The China Phase II trial will be an extension of a U.S. Phase II trial that is expected to be initiated in **3Q15**.

In previous Phase I trials of ENMD-2076, partial response and 6-month progression free survival (PFS) patients not only included TNBC, STS and ovarian cancer, but also included advanced fibrolamellar carcinoma **(FLC).** The following chart showed very promising result of ENMD-2076 for the treatment of FLC patient in the Phase I trial.



Source: company presentation

Scientifically there is a strong rationale that ENMD-2076 may provide clinical benefits to FLC patients due to the fact that VEGFR, FGFR and aurora kinase are generally over expressed in liver cancer patients.

In September 2014, CASI filed an investigational new drug application (IND) with the FDA to conduct a **Phase II** trial in advanced FLC and received allowance from the Agency soon after. In February 2015, CASI held a meeting with the FDA and received the Agency's guidance on clinical and regulatory development plan.

Based on the guidance from the FDA,

- CASI plans to conduct a **single arm trial** to evaluate the objective response rate (ORR) of ENMD-2076 in FLC patients as the primary endpoint.

- The trial will be conducted as a Simon **2-stage study** with interim futility analysis released after 16 patients reach a clinical event. Futility would be declared if none of the patients experience an objective response and would result in the termination of the study.

- If, however, one or more patients experience an objective response, the study would continue with additional patients. At that time, the company would expect to meet with the FDA to discuss what clinical efficacy endpoint would be considered reasonably likely to provide clinical benefit and support an accelerated approval based on the surrogate endpoint of tumor response.

- Assuming that the results of the proposed study show that ENMD-2076 improves objective tumor response, CASI would expect to propose a confirmatory clinical trial and, in parallel, submit an **NDA for accelerated approval** based on objective tumor response rates.

- CASI will submit to the FDA a request for **breakthrough therapy** designation whenever clinical data meets the appropriate criteria.

We think the feedback from the FDA is very encouraging, which provides ENMD-2076 a clear clinical and regulatory path going forward. We are especially encouraged that ENMD-2076 could potentially gain accelerated approval if the primary endpoint is met in the Phase II study.

FLC is a **rare form** of liver cancer that usually occurs in young adults who have no history of liver disease. FLC patients typically present with a palpable abdominal mass but no symptoms, although pain, weight loss and jaundice may occur. The typical treatment is surgical removal of the tumor. When the tumor cannot be removed surgically or when there is distant spread, systemic treatment is used. Currently, there is **no standard systemic therapy regimen** for FLC**.**

Studies have shown that FLC appears to have a **better prognosis** than typical HCC. The population-based relative survival of patients with FLC in the US is 73% at 1 year and 32% at 5 years. In contrast, HCC relative survival is 26% at 1 year and 7% at 5 years.

FLC comprises approximately 5% of all hepatocellular carcinomas (HCC). The total incidence of HCC is estimated to be 780,000 each year worldwide according to the World Health Organization. Therefore, each year, approximately 39,000 people are diagnosed with FLC worldwide.

Peak sales of ENMD-2076 for FLC alone could be in the neighborhood of $200 million worldwide if we assume a reasonable cost of $50,000 for each patient and about 10% market share of new incidence when ENMD-2076 is approved for FLC.

Update on Import Drug Business Development

On July 20, CASI officially launched ZEVALIN® in Hong Kong for patients with indicated non-Hodgkin's lymphoma (NHL). The drug will be supplied by CASI and its local partner, Global Medical Solutions Hong Kong Limited.

As a reminder, CASI acquired exclusive rights **for greater China** to **Zevalin** ® (ibritumomab tiuxetan) from **Spectrum Pharmaceuticals, Inc.** in September 2014. Zevalin IV injection is a CD20-directed radiotherapeutic antibody. It is approved in the US for the treatment of relapsed or refractory, low-grade or follicular B-cell non-Hodgkin's lymphoma **(FNHL).** Zevalin is also indicated for the treatment of patients with previously untreated follicular non-Hodgkin's Lymphoma who achieve a partial or complete response to first-line chemotherapy.

Zevalin IV injection is a CD20-directed radiotherapeutic antibody. It is approved in the US for the treatment of relapsed or refractory, low-grade or follicular B-cell non-Hodgkin's lymphoma **(FNHL).** Zevalin is also indicated for the treatment of patients with previously untreated follicular non-Hodgkin's Lymphoma who achieve a partial or complete response to first-line chemotherapy. A Phase III trial in diffused large B cell lymphoma **(DLBCL)** is ongoing

Zevalin therapeutic regimen consists of two components: **rituximab**, and Yttrium-90 **(Y-90)** radiolabeled Zevalin for therapy. Zevalin builds on the combined effect of a targeted biologic monoclonal antibody augmented with the therapeutic effects of a beta-emitting radioisotope. Zevalin builds on the combined therapeutic effects of a targeted biologic monoclonal antibody augmented with a beta-emitting radioisotope.

We are pleased that CASI is launching Zevalin in Hong Kong on schedule.

Since Hong Kong is a relatively small market for oncology, we don't expect meaningful sales in Hong Kong. However, we think the launch of Zevalin in Hong Kong is strategically important to CASI in a few aspects. ***First*****,** since Hong Kong is close to mainland China, which has a much larger cancer patient population, launching Zevalin in Hong Kong will raise the drug's visibility in both Hong Kong and mainland China, which could help penetrate the China market when Zevalin gets final approval in China.

Second, CASI will also gain marketing experience from Zevalin launch in Hong Kong, which is important for the future products launch in China. ***Third,*** we believe it is the first step of the company's building up its commercialization capabilities, a record breaking in the company's history.

CASI is currently **registering Zevalin in China** and will file for marketing application in Taiwan later this year. Since Zevalin is already approved in the US, we believe that gaining approval from local regulatory authorities for commercialization in greater China will require a shorter timeframe compared to clinical-stage drugs. It usually takes about 3 to 4 years to get approval of an imported drug in China. We expect Zevalin to be approved by CFDA in 2019.

According to International Agency for Research on Cancer (IARC), annual incidence of NHL is estimated at 46,563 cases with a mortality of 29,201cases in China in 2015. The five year prevalence is estimated at 69,200 cases, including 13% of cases in FNHL and 30% of cases in DLBCL.

The retail price of Zevalin per dose in the US is approximately $50,000 and the treatment cycle is one dose. The price tag in China for imported drugs is similar to its overseas price, but usually will be 100% out of pocket cost to patients. We assume 10% penetration of the NHL market by Zevalin, which means peak sales will be approximately **$150 million or more** in China.

OVERVIEW

CASI Pharmaceuticals, Inc. (**CASI**-NASDAQ) is a commercial stage biopharmaceutical company focused on the acquisition, development and commercialization of innovative therapeutics for **cancer** and **autoimmune disease** for the global market with a commercial focus **on greater China area** including Taiwan, Hong Kong and Macau.

The company aims to become an integrated biopharmaceutical company with significant market share in China, while establishing partnerships for global development and commercialization. In order to achieve this goal, CASI has implemented a **unique business model**: pursue its internal proprietary pipeline development and at the same time acquiring additional drug candidates to build a rich product portfolio.

The **internal drug development** utilizes a **dual development strategy** to leverage its expertise and resources in North America and China to bring safer, more effective, and/or easier-to-use drugs to patients and to develop them more cost-effectively while its **import drug business** in China takes advantage of shorter timeframe of the drug registration process in the country.

CASI's internal drug pipeline includes **ENMD-2076**, a proprietary, novel, first-in-class oncology drug candidate that has demonstrated promising activity in several cancer indications. ENMD-2076 is currently in three multiple-site **Phase II** clinical trials with ongoing biomarker analysis. CASI expects to initiate a **Phase II** trial in fibrolamellar carcinoma (**FLC**) in 3Q2015.

Also included in its pipeline is **2ME2** (2-methoxyestradial) currently under **reformulation development** for autoimmune disorders. 2ME2 is an orally active compound that has antiproliferative, antiangiogenic and anti-inflammatory properties. The inhibition of angiogenesis is an important approach to the treatment of both cancer and autoimmune diseases such as rheumatoid arthritis. 2ME2 has potential as a single agent in rheumatoid arthritis based on its antiangiogenic, anti-inflammatory, and anti-osteoclastic properties. 2ME2 has also demonstrated positive preclinical results for multiple sclerosis. It can also potentially be used in combinational therapies with current standard of care products for those indications due to its excellent safety profile.



Source: company presentation

In September 2014, CASI acquired from **Spectrum Pharmaceuticals, Inc.** exclusive rights **for greater China** to three oncology products, including **Zevalin** ® (ibritumomab tiuxetan), approved in the U.S. for advanced non-Hodgkin's lymphoma, **Marqibo**® (vincristine sulfate liposome injection), approved in the U.S. for advanced adult Ph- acute lymphoblastic leukemia (ALL), as well as **Evomela™** (captisol enabled™ melphalan), which is under the FDA review for marketing approval and is expected to be approved by the FDA in October 2015.

The company has initiated the drug registration process to obtain marketing approval for these products in China and will initiate commercial activity of Zevalin® in Hong Kong.

Products under Development for Import Drug Registraion in Greater China

Product	Description	Indication	Status	Partner's Status in SPECTRUM
ZEVALIN®	ibritumomab tiuxetan injection, a CD20-directed radiotherapeutic antibody	Advanced non-Hodgkin's lymphoma (NHL)	Preparing commercial launch in Hong Kong; Preparing Import Drug Registration applications for China and Taiwan	Approved and marketed
MARQIBO®	vinCRIStine sulfate LIPOSOME injection	Advanced adult Ph- acute lymphoblastic leukemia (ALL)	Preparing Import Drug Registration applications for China, Taiwan, and Hong Kong	Approved and marketed
Captisol Enabled™ Melphalan	Captisol Enabled™ (propylene glycol-free) melphalan	Multiple myeloma (MM) transplant setting	Preparing Import Drug Registration applications for China, Taiwan, and Hong Kong	A New Drug Application filed with FDA in 2014

Source: company presentation

CASI Pharmaceuticals, Inc. was founded in 1991 and was formerly known as EntreMed, Inc. The company changed its name to CASI Pharmaceuticals, Inc. in June 2014 as part of the restructuring and turnaround of the company that started in 2012 with the investment by IDG-Accel and later Kleiner Perkins Caufield China. In the short time since, the company has established an office and R&D center in Beijing, initiated three trials for its lead drug ENMD-2076 with one trial recently expanded to China, acquired greater China rights to two U.S. approved drugs and one NDA-stage drug candidate, and has

made inroads into their second internal drug, 2ME2. We expect the momentum to continue for this company.

CASI is headquartered in Rockville, Maryland and has a wholly owned subsidiary and R&D center in Beijing, China.

INVESTMENT THESIS

ENMD-2076 for Multiple Cancers

CASI is dedicated to the development of its **proprietary pipeline**, which, we believe, will provide substantial value to the company.

The company's lead drug candidate is **ENMD-2076**, a selective Aurora A and angiogenic kinase inhibitor for the treatment of cancer. CASI is developing ENMD-2076 in the U.S. and Canada for approval by the FDA, and as part of its development strategy, has expanded its U.S. trial in triple-negative breast cancer (TNBC) to China sites, and will follow a similar pathway to include China sites for its ongoing U.S./Canada trials in advanced/metastatic soft tissue sarcoma (STS), and in advanced ovarian clear cell carcinomas (OCCC). The combined data can potentially be used to support global filings as well as import drug registrations in China.

ENMD-2076 is an **orally-active**, Aurora A/angiogenic kinase inhibitor with a unique kinase selectivity profile. ENMD-2076 exerts its effects through multiple mechanisms of action, including anti-proliferative activity and the inhibition of angiogenesis. **Aurora kinases** are key regulators of cell division, and are often over-expressed in human cancers. In addition to targeting Aurora kinase, ENMD-2076 also targets the VEGFR, Flt-3, and FGFR3 kinases which have been shown to play important roles in the development of many cancers.

ENMD: Multiple Mechanism of Action



Source: Company presentation

ENMD-2076 has demonstrated significant, dose-dependent **preclinical anti-cancer efficacy** as a single agent in multiple xenograft models (e.g. breast, colon, leukemia and liver), as well as in ex vivo human leukemia patient cells. ENMD-2076 also has shown promising activity in **Phase I** clinical trials in solid tumors including ovarian, breast, liver, renal and sarcoma, as well as in leukemia and multiple myeloma. In these tumors, ENMD-2076 achieved partial response rate of 3% and stable disease of 85% with overall response rate of 88%, which we think is very promising. The recommended dose for ENMD-2076 is 160 mg/m^2/d.



Source: company presentation

CASI also has completed a **Phase II** trial of ENMD-2076 in ovarian cancer. The company is currently conducting multiple **Phase II** studies of ENMD-2076 in triple-negative breast cancer (TNBC), advanced/metastatic soft tissue sarcoma (STS), and in advanced ovarian clear cell carcinomas (OCCC) in North America.

In addition to the clinical trials in the U.S. and Canada, CASI has received approvals from the China Food and Drug Administration (CFDA) to initiate Phase II clinical trials for ENMD-2076 in TNBC, advanced/metastatic sarcoma, and advanced ovarian clear cell carcinoma in the country. The company has initiated the TNBC trial and currently is recruiting patients while is in the planning process for trials in China for the other two indications. The clinical trials in China will supplement the company's ongoing Phase II trial currently underway in North America.

The status and development of ENMD-2076 is outlined below:

Disease Indication	*Status*
Advanced Solid tumors	Phase I trial completed
Leukemia	Phase I trial completed
Multiple Myeloma	Phase I trial completed
Ovarian Cancer	Phase II trial completed
Triple-Negative Breast Cancer	Phase II currently ongoing in both US and China
Advanced/Soft Tissue Sarcoma	Phase II currently ongoing in Canada, clinical trial application approved by CFDA, in the process of initiation in China
Healthy Volunteer	Phase I crossover bioequivalent trial being completed, Food effect study ongoing in the US
Advanced Ovarian Clear Cell Carcinoma	Phase II currently enrolling, clinical trial application approved by CFDA, in the process of initiation in China

ENMD-2076 has received orphan drug designation from the FDA for the treatment of ovarian cancer, multiple myeloma, acute myeloid leukemia and hepatocellular carcinoma (HCC).

2ME2 for Autoimmune Disease/Cancer

CASI's proprietary pipeline also includes 2ME2 for the treatment of **autoimmune disease** such as rheumatoid arthritis, multiple sclerosis, and **cancer.**

2ME2 (2-methoxyestradiol) is an orally active compound that has antiproliferative, antiangiogenic and anti-inflammatory properties. The inhibition of angiogenesis is an important approach to the treatment of both cancer and rheumatoid arthritis (RA). 2ME2 has potential as a single agent in RA based on its antiangiogenic, anti-inflammatory, and anti-osteoclastic (bone resorption) properties. It can also potentially be used in combinational therapies with current standard of care products for those indications due to its excellent safety profile.



Preclinical animal studies of 2ME2 have demonstrated significant efficacy for multiple cancers and autoimmune disease, including RA and multiple sclerosis (MS). Additional preclinical studies are ongoing in collaboration with research institutes in the US.

The following picture demonstrates strong efficacy of 2ME2 for arthritis in an animal model.



Source: company presentation

The company also completed multiple **Phase I and II** clinical studies in cancer patients with solid tumors and multiple myeloma. 2ME2 has demonstrated excellent safety profile and promising activities in these studies. The previous clinical challenge for the product is attributed to its very poor bioavailability, which

prohibited the reach of optimal therapeutic level in patients. The current development focus is to improve product solubility and bioavailability through its internal novel drug delivery technology platform.

CASI has filed an IND of 2ME2 with the FDA for rheumatoid arthritis and is exploring multiple strategies for the development of 2ME2 including potential internal development and partnership opportunities.

More Imported Drugs Will be Launched in China

In addition to Zevalin, CASI is also in the process of registering Marqibo in China and we estimate it will be approved in 2020.

Marqibo is a novel, **liposome-encapsulated**, formulation of **vincristine sulfate**, a microtubule inhibitor. Marqibo is approved in the US for the treatment of adult patients with Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia **(ALL)** in second or greater relapse or whose disease has progressed following two or more anti-leukemia therapies.

Spectrum is also conducting a **Phase III** trial of Marqibo for front line treatment of aggressive NHL and **Phase III** trial for front line treatment of adult Ph(-) ALL in the US. Once these new indications are approved by the FDA, CASI plans to expand the same indications in China.

Since Marqibo is already approved in the US, it falls into the imported drug registration process category, which takes a shorter timeframe for gaining marketing approval in China than clinical stage candidates.

According to IARC, annual incidence of leukemia is estimated at 70,240 cases with a mortality of 58,746 cases in China in 2015. The five-year prevalence of leukemia is estimated at 73,694 cases including approximately 10,000 Ph(-) adult ALL. The retail cost of Marqibo in the US is approximately $11,700 per dose, and treatment cycle is 28 days, 4 doses per cycle, multiple cycle regimen.

We assume 10% market penetration, the peak sales of Marqibo will be about **$40 million for one cycle** treatment in China. When treatment cycles increase and new indications are added, the sales will increase accordingly.

Evomela for Multiple Myeloma, A Great Commercial Opportunity in China

The third imported drug is **Evomela™** (captisol-enabled PG-free melphalan).

Melphalan inhibits DNA replication and transcription causing cytotoxicity in dividing and non-dividing cells including multiple myeloma. Evomela is a new propylene glycol (PG)-free IV formulation of melphalan developed for a high-dose conditioning treatment prior to hematopoietic stem cell transplantation (HSCT) in patients suffering from multiple myeloma (MM) and for the palliative treatment of multiple myeloma patients for whom oral therapy is not appropriate. Evomela completely avoids the use of PG, which is used as a co-solvent in the current formulation of melphalan and has been reported to cause renal and cardiac side-effects that limit the ability to deliver higher quantities of intended therapeutic compounds. The use of captisol technology to reformulate melphalan is anticipated to allow for longer administration durations and slower infusion rates, potentially enabling clinicians to avoid reductions and safely achieve a higher dose intensity of pre-transplant chemotherapy.

Spectrum Pharmaceuticals, Inc. filed a NDA with the FDA in December 2014. We expect Evomela to be approved in October 2015. CASI will submit import drug registration application for Evomela in greater China after its approval by the FDA in the US. We estimate Evomela will be approved in China in 2020 if it can get approval in 2015 by the FDA.

IARC estimates that approximately 12,197 new MM patients will be diagnosed with a mortality of 9,038 cases in China in 2015. The five-year prevalence of MM in China is estimated at 14,100 cases. **Branded**

or generic melphalan is currently not available in China. This gives CASI a great opportunity to promote and expand Evomela in China once it is approved by the CFDA.

Market Opportunity in China

CASI's mission is to become an integrated biopharmaceutical company with a commercial focus on greater China area. The company's wholly-owned Chinese subsidiary is aggressively executing the China portion of its drug development strategy, including seeking regulatory approvals and conducting local clinical trials, pursuing local funding opportunities and strategic collaborations, and implementing the company's plan for development and commercialization in the Chinese market.

The company's **dual drug development strategy** allows CASI to continue to tap into the front-line innovations in the U.S. and to incorporate China as a significant clinical location to advance drug development with reduced costs, large patient population in multiple indications, and accumulation of data that supports a global registration strategy.

In addition to China as a strategic clinical location, CASI is also focused on the China commercial opportunity. China is the fastest growing pharmaceutical market in the world. With the rapid growth of the country's economy and increased spending in healthcare by both the government and private sector, China is projected to be the 2nd largest pharmaceutical market by 2016 and the largest oncology market by 2019.



Cancer has been a big challenge for the China healthcare industry. Both incidence and death rate for cancer have been rising dramatically in China and around the world. For example, cancer incidence is estimated to reach 1.7 million in the US and 3.4 million in China in 2015, which is expected to increase to

2.1 million in the US and 4.4 million in China by 2025. Five year prevalence is approximately 4.8 million in the US and 5 million in China.

Currently, there is no leading brand oncology company in China and most leading local Chinese pharmaceutical companies achieved success through branded generics. A company acquiring innovative oncology products from the West and commercializing in China with scale and efficiency will have a significant lead to become a major market participant. We believe CASI with time can achieve this.

We believe CASI will become a key player in China's oncology market in about five years when both imported and locally approved cancer drugs become the choice of oncologists in China.

There are also unmet medical needs in China for autoimmune disease and CASI's 2ME2 has the potential to tap this multi-billion dollar market.



Source: prevention strategy of cancer in Eastern Asia

VALUATION AND RECOMMENDATION

We maintain our **Buy** rating on CASI shares and reiterate our price target of **$4.50** per share.

CASI is a commercial stage biopharmaceutical company focusing on the development and commercialization of therapeutics for cancer and autoimmune disease and is competitively positioned with an integrated U.S./China drug development model. In addition to China as a strategic clinical location, CASI is also focused on the China commercial opportunity, China being projected to be the 2nd largest pharmaceutical market by 2016 and the largest oncology market by 2019.

CASI currently has three products in various stages of the import drug registration process with CFDA in China, with one product (Zevalin) officially launched in Hong Kong. Two of these three products are approved in the U.S. and marketed by its collaborator Spectrum Pharmaceuticals, Inc. and a NDA is filed for the third drug with the U.S. FDA in December 2014. Product revenue will be generated in 2015 for the

first time in the company's history. When all three products are approved in China (we estimate the approval in 2019 or 2020), CASI will become a key player in China's oncology market and revenue could increase dramatically due to rapid market penetration.

In addition to imported drugs from the US, CASI is also developing its proprietary pipeline with two lead candidates ENMD-2076 for cancers and 2ME2 for autoimmune disease using its **unique dual drug development strategy.** This dual drug development approach leverages the company's expertise and resources in both the U.S. and China**,** which has many advantages over traditional drug development approaches. These advantages include low cost, high productivity due to large talent pool in China, and large patient pool for clinical trials.

ENMD-2076 is already in multiple **Phase II** clinical trials targeting breast cancer, soft tissue sarcoma, and ovarian clear cell carcinoma. A new Phase II trial will be initiated in 3Q15 to target fibrolamellar carcinoma (FLC). The company also plans to initiate human PK clinical trial of 2ME2 prior to the end of 2015.

CASI also has a strong balance sheet, which will last through the end of 2016, and an experienced management team, who, we believe, is able to lead the company to the next level.

When it comes to the valuation, we believe CASI's shares are undervalued at the current market price based on the company's strong fundamentals. Currently, shares of the company are trading at around $1.40 per share which values the company at $45 million in market cap based on approximately 32.5 million outstanding shares. We believe this undervalues the company based on what we have discussed above.

Based on our long term financial model, we expect CASI to become profitable in 2020 with an EPS of $0.01 based on total revenue of $25 million. EPS will grow to $0.58 while revenue will reach $65 million in fiscal 2021. If we use the average biotech P/E ratio of 30x, using 25% discount rate for six years, we come up with our price target of $4.50 per share. This price target values the company at $146 million in market cap, which is still conservative in our view.

However, there are some **risks** associated with our price target.

Our price target assumes the final approval of the three imported drugs in 2019 or 2020 in China and the final approval of ENMD-2076 and 2ME2. Although risks associated with imported drug registration are relatively low in China, we can't completely rule out the possibility of disapproval, or delay of the approval.

Further, ENMD-2076 and 2ME2 are still in the development stage. The risks associated with drug development are high, especially for early stage candidates. Both ENMD-2076 and 2ME2 have a high hurdle to overcome both clinically and regulatorily. Any delay or failure in clinical development or regulatory approval will cause the share price to decline dramatically.

Cash burn is also a concern. While current cash can last into 3Q2016, CASI may need to raise new funds to finance its clinical programs and operations until it can generate positive cash flow in 2020. We remind investors that any equity financing will dilute the existing shareholder base and may cause the share price to fall.

PROJECTED INCOME STATEMENT

	2013 (Dec)	2014 (Dec)	2015 (Dec)					2016 (Dec)	2017 (Dec)	2018 (Dec)	2019 (Dec)	2020 (Dec)	2021 (Dec)
$ in million except per share data	FY	FY	Q1	Q2	Q3	Q4	FYE	FYE	FYE	FYE	FYE	FYE	FYE
Grant revenue	$0.00	$0.02	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Royalties	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Product revenue	$0.00	$0.00	$0.02	$0.02	$0.10	$0.20	$0.35	$0.50	$1.00	$2.00	$10.00	$25.00	$65.00
Total Revenues	**$0.00**	**$0.02**	**$0.02**	**$0.02**	**$0.10**	**$0.20**	**$0.35**	**$0.50**	**$1.00**	**$2.00**	**$10.00**	**$25.00**	**$65.00**
YOY Growth	-	-	-	-	-	-	-	-	-	-	-	-	-
CoGS	0.00	0.00	0.01	0.00	0.03	0.05	0.09	0.13	0.25	0.50	2.00	5.00	13.00
Gross Income	**$0.00**	**$0.02**	**$0.02**	**$0.02**	**$0.08**	**$0.15**	**$0.26**	**$0.38**	**$0.75**	**$1.50**	**$8.00**	**$20.00**	**$52.00**
Gross Margin	-	-	73.6%	88.6%	75.0%	75.0%	75.0%	75.0%	75.0%	75.0%	80.0%	80.0%	80.0%
R&D	$2.75	$2.77	$0.87	$1.22	$0.90	$1.00	$3.99	$4.00	$4.50	$6.00	$7.50	$9.00	$10.50
% R&D	-	-	-	-	-	-	-	-	-	-	-	-	-
SG&A	$2.99	$3.76	$0.92	$0.86	$1.20	$1.40	$4.38	$5.50	$6.50	$8.00	$9.50	$10.50	$12.50
%SG&A	-	-	-	-	-	-	-	-	-	-	-	-	-
Other Expenses	$0.00	$19.68	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Operating Income	**($5.7)**	**($26.2)**	**($1.8)**	**($2.1)**	**($2.0)**	**($2.3)**	**($8.1)**	**($9.1)**	**($10.3)**	**($12.5)**	**($9.0)**	**$0.5**	**$29.0**
Operating Margin	-	-	-	-	-	-	-	-	-	-	-	-	44.62%
Other Net	$0.0	$0.0	($0.0)	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	($0.1)	($0.1)	($0.1)
Pre-Tax Income	**($5.7)**	**($26.2)**	**($1.8)**	**($2.0)**	**($2.0)**	**($2.3)**	**($8.1)**	**($9.1)**	**($10.3)**	**($12.5)**	**($9.1)**	**$0.4**	**$28.9**
Income taxes(benefit)	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0
Tax Rate	-	-	-	-	-	-	-	-	-	-	-	-	-
Reported Net Income	**($5.7)**	**($26.2)**	**($1.8)**	**($2.0)**	**($2.0)**	**($2.3)**	**($8.1)**	**($9.1)**	**($10.3)**	**($12.5)**	**($9.1)**	**$0.4**	**$28.9**
YOY Growth	-	-	-	-	-	-	-	-	-	-	-	-	
Net Margin	-	-	-	-	-	-	-						
Diluted Shares Out	26.1	28.6	32.4	32.4	33.0	35.0	33.2	40.0	45.0	38.0	45.0	48.0	50.0
Reported EPS	**($0.22)**	**($0.92)**	**($0.06)**	**($0.06)**	**($0.06)**	**($0.06)**	**($0.24)**	**($0.23)**	**($0.23)**	**($0.33)**	**($0.20)**	**$0.01**	**$0.58**
One time charge	*$0.00*	*$19.68*	*$0.00*	*$0.00*	*$0.00*	*$0.00*	*$0.00*	*$0.00*	*$0.00*	*$0.00*	*$0.00*	*$0.00*	*$0.00*
Non GAAP Net Income	**($5.7)**	**($6.5)**	**($1.8)**	**($2.0)**	**($2.0)**	**($2.3)**	**($8.1)**	**($9.1)**	**($10.3)**	**($12.5)**	**($9.1)**	**$0.4**	**$28.9**
Non GAAP EPS	**($0.22)**	**($0.23)**	**($0.06)**	**($0.06)**	**($0.06)**	**($0.06)**	**($0.24)**	**($0.23)**	**($0.23)**	**($0.33)**	**($0.20)**	**$0.01**	**$0.58**

Source: Company filings and Zacks estimates

© Copyright 2015, Zacks Investment Research. All Rights Reserved.

HISTORICAL ZACKS RECOMMENDATIONS



DISCLOSURES

The following disclosures relate to relationships between Zacks Small-Cap Research ("Zacks SCR"), a division of Zacks Investment Research ("ZIR"), and the issuers covered by the Zacks SCR Analysts in the Small-Cap Universe.

ANALYST DISCLOSURES

I, Grant Zeng, CFA, hereby certify that the view expressed in this research report accurately reflect my personal views about the subject securities and issuers. I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the recommendations or views expressed in this research report. I believe the information used for the creation of this report has been obtained from sources I considered to be reliable, but I can neither guarantee nor represent the completeness or accuracy of the information herewith. Such information and the opinions expressed are subject to change without notice.

INVESMENT BANKING, REFERRALS, AND FEES FOR SERVICE

Zacks SCR does not provide nor has received compensation for investment banking services on the securities covered in this report. Zacks SCR does not expect to receive compensation for investment banking services on the Small-Cap Universe. Zacks SCR may seek to provide referrals for a fee to investment banks. Zacks & Co., a separate legal entity from ZIR, is, among others, one of these investment banks. Referrals may include securities and issuers noted in this report. Zacks & Co. may have paid referral fees to Zacks SCR related to some of the securities and issuers noted in this report. From time to time, Zacks SCR pays investment banks, including Zacks & Co., a referral fee for research coverage.

Zacks SCR has received compensation for non-investment banking services on the Small-Cap Universe, and expects to receive additional compensation for non-investment banking services on the Small-Cap Universe, paid by issuers of securities covered by Zacks SCR Analysts. Non-investment banking services include investor relations services and software, financial database analysis, advertising services, brokerage services, advisory services, equity research, investment management, non-deal road shows, and attendance fees for conferences sponsored or co-sponsored by Zacks SCR. The fees for these services vary on a per client basis and are subject to the number of services contracted. Fees typically range between ten thousand and fifty thousand USD per annum.

© Copyright 2015, Zacks Investment Research. All Rights Reserved.

POLICY DISCLOSURES

Zacks SCR Analysts are restricted from holding or trading securities placed on the ZIR, SCR, or Zacks & Co. restricted list, which may include issuers in the Small-Cap Universe. ZIR and Zacks SCR do not make a market in any security nor do they act as dealers in securities. Each Zacks SCR Analyst has full discretion on the rating and price target based on his or her own due diligence. Analysts are paid in part based on the overall profitability of Zacks SCR. Such profitability is derived from a variety of sources and includes payments received from issuers of securities covered by Zacks SCR for services described above. No part of analyst compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in any report or article.

ADDITIONAL INFORMATION

Additional information is available upon request. Zacks SCR reports are based on data obtained from sources we believe to be reliable, but are not guaranteed as to be accurate nor do we purport to be complete. Because of individual objectives, this report should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed by Zacks SCR Analysts are subject to change without notice. Reports are not to be construed as an offer or solicitation of an offer to buy or sell the securities herein mentioned.

ZACKS RATING & RECOMMENDATION

ZIR uses the following rating system for the 1121 companies whose securities it covers, including securities covered by Zacks SCR:
Buy/Outperform: The analyst expects that the subject company will outperform the broader U.S. equity market over the next one to two quarters.
Hold/Neutral: The analyst expects that the company will perform in line with the broader U.S. equity market over the next one to two quarters.
Sell/Underperform: The analyst expects the company will underperform the broader U.S. Equity market over the next one to two quarters.

The current distribution is as follows: Buy/Outperform- 15.3%, Hold/Neutral- 76.9%, Sell/Underperform – 7.2%. Data is as of midnight on the business day immediately prior to this publication.